Blinatumomab: first global approval. - Wikidata - wikimedia - TriplyDB

Blinatumomab: first global approval.

Blinatumomab: first global approval.

http://www.wikidata.org/entity/Q38338407

about

The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6 T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful.Targeting B-cell maturation antigen in multiple myeloma.Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation Emerging biological therapies to treat acute lymphoblastic leukemia.T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC.Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity.Agents in Development for Childhood Acute Lymphoblastic Leukemia.A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells

P2860

Q26744280-C57FA75B-9468-4C64-BA34-65EDF6B6EAC4 Q36171935-C0DD28B1-F3A2-4C7F-BF1C-5FFA2467C93A Q36421292-7439AC7D-358A-4876-B3C6-96693BE0D92D Q36821083-89843D27-8F9D-4740-ABC4-BC2F17E46C27 Q36965071-35DC1D8C-060E-4745-9FA5-3E15B91C435F Q37457329-BA98EBCF-8A6B-46BC-B7D5-CCEF0174EC45 Q37589543-20F5435F-C596-43C4-9252-509A64A9D3E2 Q38586922-1313B7E0-AA51-495D-BE29-5324D3319F5F Q38707896-E7696D66-119D-402E-A8F1-2D652871050A Q38974641-E4B7B80C-3CBB-4A3C-ABFA-856FC211A5AB Q39002036-E20FE1FB-1E26-431D-9225-12EEC7B1F2CF Q40064011-F615E19D-D4D6-4CD5-B700-4591A108C822 Q41719908-393098DB-4492-43C5-BF74-CAE84EE102D5 Q47837260-4E4AB32A-CFFD-40D6-BE8C-0E7DDDC566F4 Q51233981-96999518-34D0-4B3D-9C38-4C552A4A1802 Q59134014-30BE9223-D463-49A1-8281-DCD0112AFC44

P2860

Blinatumomab: first global approval.

http://www.wikidata.org/entity/Q38338407

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Blinatumomab: first global approval.

@en

type

label

Blinatumomab: first global approval.

@en

prefLabel

Blinatumomab: first global approval.

@en

P1433

Q38338407-9FF63837-A306-4E26-A454-F65B26DF81E2

P1476

Q38338407-ED6288B8-205D-4E83-A990-D53BE320966F

P2093

Q38338407-1B32ECA4-3D80-4292-BA18-546475F8B72D

P2860

Q38338407-3237A163-8637-4D2A-99D4-934D20B32871

Q38338407-4CC285A7-B3A6-4143-AE67-B1CFC02C0723

Q38338407-6005AA31-0B18-41E0-A20D-AC740039277F

Q38338407-731EA0D2-FA04-4F73-B396-461FF8D71275

Q38338407-8379066C-3D4E-4808-BC4E-5E7B2F4539E6

Q38338407-979F2D61-D050-4105-A597-BFDDF7F5B1AD

Q38338407-ABE0E18B-ECF5-4010-AA02-378FDE59B409

Q38338407-CC9657AB-F974-4F64-BB81-4EA64BA28744

P2888

Q38338407-3F5F0F31-B1AD-47C2-AA03-3A9C57E32FA0

P304

Q38338407-2E12F1D8-1AE5-49BE-A8E3-7DA3981B5D10

P31

Q38338407-7060DE5E-BBC4-4031-88AD-F742ACD2642F

P356

Q38338407-2ABA315D-FC32-45A5-A406-B3F8545808AE

P433

Q38338407-7850AEAA-14F5-45CC-84F6-E3F6FA9130E9

P478

Q38338407-3C410D5A-7D2C-48F1-8F13-BB5A3E23484D

P577

Q38338407-B7BE7C6C-C189-4B8F-A7FF-0C555BED5C85

P6179

Q38338407-D3EA952B-3786-4389-8F1F-93DB0C233BBE

P698

Q38338407-B894AF56-6F24-4AE8-966E-311D3DA401F8

P356

S40265-015-0356-3

P1433

P1476

Blinatumomab: first global approval.

@en

P2093

Mark Sanford

http://www.w3.org/2001/XMLSchema#string

P2860

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells.

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.

Sorafenib in patients with refractory or recurrent multiple myeloma.

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

P2888

s40265-015-0356-3

P304

321-327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-015-0356-3

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1029718086

http://www.w3.org/2001/XMLSchema#string

P698

25637301

http://www.w3.org/2001/XMLSchema#string